Skip to main content
Clinical Trials/NCT05536206
NCT05536206
Completed
Not Applicable

Continuous and Wireless Vital Sign Monitoring in Patients at Home After Acute Medical Admission

Bispebjerg Hospital1 site in 1 country30 target enrollmentDecember 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Vital Sign Monitoring
Sponsor
Bispebjerg Hospital
Enrollment
30
Locations
1
Primary Endpoint
Duration of data collection from the Lifetouch patch
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The current study aims to investigate the feasibility of transmitting continuous and wireless vital sign data in real time from patients home to the hospital in patients discharged after an acute medical hospitalization

Detailed Description

The healthcare system is challenged by an aging patient population with chronic diseases, and acute admissions must be housed in hospitals with fewer beds and less staff resources. This increases the need for earlier discharge and for treatment shifted to the patients' own home. Furthermore, the transition from the hospital to the home setting is one of potential hazard, due to the lack of observation and intervention possibilities. This study aims to investigate the feasibility of wireless, continuous monitoring of patients in the days around discharge after an acute medical hospitalization, as well as occurrence of deviating vital signs i in the patients' own homes during the first days after discharge. Data will be transmitted continuously in real time from patient's homes to mobile applications for portable handheld devices such as healthcare personnel's smartphones.

Registry
clinicaltrials.gov
Start Date
December 1, 2022
End Date
July 30, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Emilie Sigvardt

MD

Bispebjerg Hospital

Eligibility Criteria

Inclusion Criteria

  • Adult patients (≥18 years) Admitted with an acute medical disease and scheduled for discharge to their own homes within five days from inclusion.

Exclusion Criteria

  • Allergy to plaster, plastic, or silicone.
  • A pacemaker or Implantable Cardioverter Defibrillator (ICD) device.
  • If the patient was deemed not able to open the front door when visited by the investigator.
  • Inability to give informed consent.

Outcomes

Primary Outcomes

Duration of data collection from the Lifetouch patch

Time Frame: Up to 72 hours of monitoring

Secondary Outcomes

  • Number of events with SpO2 < 88% in at least 10 consecutive minutes(Up to 72 hours of monitoring)
  • Number of deviating vital parameters in accordance to defined microevents(Up to 72 hours of monitoring)
  • Number of events with SpO2 < 85% in at least 5 consecutive minutes(Up to 72 hours of monitoring)
  • Duration of complete peripheral saturation data(Up to 72 hours of monitoring)
  • Duration of complete blood pressure data(Up to 72 hours of monitoring)
  • Cummulated duration of desaturation(Up to 72 hours of monitoring)

Study Sites (1)

Loading locations...

Similar Trials